drugset / Trial / NCT03727724
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
Phase 2
Completed
37 enrolled
The Netherlands Cancer Institute
Boehringer Ingelheim · collabMerck Serono International SA · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.
Timeline
- Start
- 2018-12-04
- Primary completion
- 2022-09-06
- Completion
- 2022-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |